Conference abstractPublished 24 Feb 2020
Novel approaches for the development of live attenuated influenza vaccines
North China Pharmaceutical Company, China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Influenza virus still represents a considerable threat to global public health, despite the advances in the development and wide use of influenza vaccines. Vaccination with traditional inactivate influenza vaccines (IIV) or live-attenuated influenza vaccines (LAIV) remains the main strategy in the control of annual seasonal epidemics but it does not offer protection against new influenza viruses with pandemic potential those that have shifted. Moreover, the continual antigenic drift of seasonal circulating influenza viruses requiring yearly reformulation of seasonal influenza vaccines, seriously compromises vaccine efficacy. Therefore, the quick optimization of vaccine production for seasonal influenza and the development of new vaccine approaches for pandemic viruses is still a challenge for the prevention of influenza infections. Moreover, recent reports have questioned the effectiveness of the current LAIV because of limited protection, mainly against the influenza a virus (IAV) component of the vaccine. Although the reasons for the poor protection efficacy of the LAIV have not yet been elucidated, researchers are encouraged to develop new vaccines that overcome the limitations that are associated with the current LAIV. The discovery and implementation of plasmid-based reverse genetics has been a key advance in the rapid generation of recombinant attenuated influenza viruses that can be used for the development of new and most effective LAIV. In this review, we provide an update regarding the progress that has been made during the last five years in the development of new LAIV and the innovative ways that are being explored as alternatives to the currently licensed LAIV. The safety, immunogenicity and protection efficacy profile of these new LAIVs reveal their possibility in combating influenza infections. However, efforts by vaccine companies and government agencies will be needed for developing and approving respectively these new vaccine methodologies for the control of influenza infections.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Infectious Diseases & Preventive Medicine
- SubjectInfectious Diseases
- SubjectPublic Health & Epidemiology
- BylineArticles whose byline prints “Huan Xu”
